Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies

Published on Oct 1, 2018in Pain6.03
· DOI :10.1097/j.pain.0000000000001293
Emily Stockings13
Estimated H-index: 13
Gabrielle Campbell15
Estimated H-index: 15
+ 7 AuthorsLouisa Degenhardt89
Estimated H-index: 89
This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials. gov were searched in July 2017. Analyses were conducted using Revman 5.3 and Stata 15.0. A total of 91 publications containing 104 studies were eligible (n = 9958 participants), including 47 randomised controlled trials (RCTs) and 57 observational studies. Forty-eight studies examined neuropathic pain, 7 studies examined fibromyalgia, 1 rheumatoid arthritis, and 48 other CNCP (13 multiple sclerosis-related pain, 6 visceral pain, and 29 samples with mixed or undefined CNCP). Across RCTs, pooled event rates (PERs) for 30% reduction in pain were 29.0% (cannabinoids) vs 25.9% (placebo); significant effect for cannabinoids was found; number needed to treat to benefit was 24 (95% confidence interval [CI] 15-61); for 50% reduction in pain, PERs were 18.2% vs 14.4%; no significant difference was observed. Pooled change in pain intensity (standardised mean difference:-0.14, 95% CI-0.20 to -0.08) was equivalent to a 3mm reduction on a 100 mm visual analogue scale greater than placebo groups. In RCTs, PERs for all-cause adverse events were 81.2% vs 66.2%; number needed to treat to harm: 6 (95% CI 5-8). There were no significant impacts on physical or emotional functioning, and low-quality evidence of improved sleep and patient global impression of change. Evidence for effectiveness of cannabinoids in CNCP is limited. Effects suggest that number needed to treat to benefit is high, and number needed to treat to harm is low, with limited impact on other domains. It seems unlikely that cannabinoids are highly effective medicines for CNCP.
  • References (0)
  • Citations (16)
Cited By16
#1Jürgen RehmH-Index: 101
#2Tara Elton-Marshall (Mental Health Research Institute)H-Index: 2
Last.Jakob Manthey (TUD: Dresden University of Technology)H-Index: 8
view all 4 authors...
#1Wajd Alkabbani (UM: University of Manitoba)
#2Ruth Ann Marrie (UM: University of Manitoba)H-Index: 38
Last.Christine Leong (UM: University of Manitoba)H-Index: 9
view all 7 authors...
#1Mari Kannan Maharajan (International Medical University)H-Index: 4
#2Yu Jing Yong (International Medical University)
Last.Kai Xian Yap (International Medical University)
view all 8 authors...
#1Kevin F. Boehnke (UM: University of Michigan)H-Index: 5
#2J. Ryan Scott (UM: University of Michigan)H-Index: 2
Last.Daniel J. Clauw (UM: University of Michigan)H-Index: 63
view all 6 authors...
View next paperThe research gap in chronic paediatric pain: A systematic review of randomised controlled trials